Top 10 Medical AI Companies to Buy According to Analysts

2. Simulations Plus, Inc. (NASDAQ:SLP)

Stock Upside Potential: 97.27%

Number of Hedge Fund Holders: 13

Simulations Plus, Inc. (NASDAQ:SLP) is one of the top 10 medical AI companies to buy according to analysts. On July 29, the company confirmed that its artificial intelligence-driven drug design collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) has yielded promising results.

The positive results relate to the development of novel compounds targeting inflammation and immune responses. The results show that 70% of the 27 compounds designed using the ADMET Predictor software demonstrated significant inhibition of RORyT activity. The outcomes support the company’s algorithms and platform, which utilize machine learning and artificial intelligence to develop and optimize drugs for specific targets, providing clients with a first-to-invent advantage.

Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences have been collaborating on developing RORγ/RORγT ligands. These molecules impact gene expression related to inflammation and immune responses.

Simulations Plus, Inc. (NASDAQ:SLP) integrates AI and machine learning (ML) into its modeling and simulation software to enhance drug discovery and development. It leverages AI/ML to predict drug behavior in the body, optimize chemical compounds, and accelerate the overall drug development process.